Warren Buffett’s Latest Portfolio: 5 Dividend Stock Picks

In this article, we discuss the 5 best dividend stocks in Warren Buffett’s latest 13F portfolio. If you want to read our detailed analysis of Berkshire Hathaway’s past performance and Buffett’s investment strategies, be sure to read Warren Buffett’s Latest Portfolio: 10 Dividend Stock Picks. 

5. AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 82

Berkshire Hathaway’s Stake Value: $410,744,000

Dividend Yield as of February 21: 3.92%

On October 29, AbbVie Inc. (NYSE:ABBV), an American biopharmaceutical company, hiked its quarterly dividend by 9% to $1.41 per share, which yields 3.92% as of February 21. The company has raised its dividend by over 250% since its inception in 2013.

The number of hedge funds tracked by Insider Monkey holding stakes in AbbVie Inc. (NYSE:ABBV) inched up to 82 in Q4 from 81 in the previous quarter. These stakes hold a consolidated value of over $3.7 billion.

In February, JPMorgan praised AbbVie Inc. (NYSE:ABBV)’s Q4 results and its developments in immunology. The firm lifted its price target on the stock to $185, while maintaining an ‘Overweight’ rating on the shares. Warren Buffett started investing in AbbVie Inc. (NYSE:ABBV) during the third quarter of 2020. In Q4 2021, Berkshire Hathaway held stakes worth over $410.7 million after slashing its position in the company by 79%. AbbVie Inc. (NYSE:ABBV) accounted for 0.12% of Warren Buffett’s portfolio.

Miller Howard Investments mentioned AbbVie Inc. (NYSE:ABBV) in its Q3 2021 investor letter. Here is what the firm had to say:

“While optimistic about a recovery, we continue to balance our cyclical holdings with dividend-payers in stable, less economically-sensitive industries. We hold three pharmaceutical companies, (which includes) AbbVie (ABBV). All three have strong cash flows and balance sheets, making their high dividends reasonably safe. The investment controversy surrounding these pharma companies is whether they can develop or acquire new products to replace their current blockbuster drugs. The low valuations on these stocks reflects what we believe to be undue pessimism by investors on the prospects for new drugs.”